Cargando…
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
BACKGROUND: Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies showed high anti-tumor efficacy and made conversion resection possible for patients with unresectable hepatocellular carcinoma (HCC). However, long-term survival has not been reported. METHODS: A cohort of...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085942/ https://www.ncbi.nlm.nih.gov/pubmed/36178565 http://dx.doi.org/10.1245/s10434-022-12530-z |
_version_ | 1785022036808040448 |
---|---|
author | Zhu, Xiao-Dong Huang, Cheng Shen, Ying-Hao Xu, Bin Ge, Ning-Ling Ji, Yuan Qu, Xu-Dong Chen, Lingli Chen, Yi Li, Mei-Ling Zhu, Jin-Jin Tang, Zhao-You Zhou, Jian Fan, Jia Sun, Hui-Chuan |
author_facet | Zhu, Xiao-Dong Huang, Cheng Shen, Ying-Hao Xu, Bin Ge, Ning-Ling Ji, Yuan Qu, Xu-Dong Chen, Lingli Chen, Yi Li, Mei-Ling Zhu, Jin-Jin Tang, Zhao-You Zhou, Jian Fan, Jia Sun, Hui-Chuan |
author_sort | Zhu, Xiao-Dong |
collection | PubMed |
description | BACKGROUND: Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies showed high anti-tumor efficacy and made conversion resection possible for patients with unresectable hepatocellular carcinoma (HCC). However, long-term survival has not been reported. METHODS: A cohort of consecutive patients who received combined TKI/anti-PD-1 antibodies as first-line treatment for initially unresectable HCC at the authors’ hospital between August 2018 and September 2020 was eligible for this study. Patients who were responding to systemic therapy and met the criteria for hepatectomy underwent liver resection with curative intention. The study also investigated the association of clinical factors with successful conversion resection and postoperative recurrence. RESULTS: The study enrolled 101 patients including 24 patients (23.8 %) who underwent R0 resection a median of 3.9 months (interquartile range: 2.5–5.9 months) after initiation of systemic therapy. Patients with an Eastern cooperative oncology group performance status of 0, fewer intrahepatic tumors, or a radiographic response to systemic therapy were more likely to be able to receive curative resection. After a median follow-up period of 21.5 months, hepatectomy was independently associated with a favorable overall survival (hazard ratio [HR], 0.050; 95 % confidence interval [CI], 0.007–0.365; P = 0.003). For the 24 patients who underwent surgery, the 12-month recurrence-free survival and overall survival rates were respectively 75% and 95.8%. Achieving a pathologic complete response (n = 10) to systemic therapy was associated with a favorable recurrence-free survival after resection, with a trend toward significance (HR, 0.345; 95% CI, 0.067–1.785; P = 0.187). CONCLUSIONS: Selected patients with initially unresectable HCC can undergo hepatectomy after systemic therapy with combined TKI/anti-PD-1 antibodies. In this study, conversion resection was associated with a favorable prognosis. |
format | Online Article Text |
id | pubmed-10085942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-100859422023-04-12 Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma Zhu, Xiao-Dong Huang, Cheng Shen, Ying-Hao Xu, Bin Ge, Ning-Ling Ji, Yuan Qu, Xu-Dong Chen, Lingli Chen, Yi Li, Mei-Ling Zhu, Jin-Jin Tang, Zhao-You Zhou, Jian Fan, Jia Sun, Hui-Chuan Ann Surg Oncol Hepatobiliary Tumors BACKGROUND: Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies showed high anti-tumor efficacy and made conversion resection possible for patients with unresectable hepatocellular carcinoma (HCC). However, long-term survival has not been reported. METHODS: A cohort of consecutive patients who received combined TKI/anti-PD-1 antibodies as first-line treatment for initially unresectable HCC at the authors’ hospital between August 2018 and September 2020 was eligible for this study. Patients who were responding to systemic therapy and met the criteria for hepatectomy underwent liver resection with curative intention. The study also investigated the association of clinical factors with successful conversion resection and postoperative recurrence. RESULTS: The study enrolled 101 patients including 24 patients (23.8 %) who underwent R0 resection a median of 3.9 months (interquartile range: 2.5–5.9 months) after initiation of systemic therapy. Patients with an Eastern cooperative oncology group performance status of 0, fewer intrahepatic tumors, or a radiographic response to systemic therapy were more likely to be able to receive curative resection. After a median follow-up period of 21.5 months, hepatectomy was independently associated with a favorable overall survival (hazard ratio [HR], 0.050; 95 % confidence interval [CI], 0.007–0.365; P = 0.003). For the 24 patients who underwent surgery, the 12-month recurrence-free survival and overall survival rates were respectively 75% and 95.8%. Achieving a pathologic complete response (n = 10) to systemic therapy was associated with a favorable recurrence-free survival after resection, with a trend toward significance (HR, 0.345; 95% CI, 0.067–1.785; P = 0.187). CONCLUSIONS: Selected patients with initially unresectable HCC can undergo hepatectomy after systemic therapy with combined TKI/anti-PD-1 antibodies. In this study, conversion resection was associated with a favorable prognosis. Springer International Publishing 2022-09-30 2023 /pmc/articles/PMC10085942/ /pubmed/36178565 http://dx.doi.org/10.1245/s10434-022-12530-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Hepatobiliary Tumors Zhu, Xiao-Dong Huang, Cheng Shen, Ying-Hao Xu, Bin Ge, Ning-Ling Ji, Yuan Qu, Xu-Dong Chen, Lingli Chen, Yi Li, Mei-Ling Zhu, Jin-Jin Tang, Zhao-You Zhou, Jian Fan, Jia Sun, Hui-Chuan Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title | Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_full | Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_fullStr | Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_full_unstemmed | Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_short | Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_sort | hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-pd-1 antibody therapy for patients with unresectable hepatocellular carcinoma |
topic | Hepatobiliary Tumors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085942/ https://www.ncbi.nlm.nih.gov/pubmed/36178565 http://dx.doi.org/10.1245/s10434-022-12530-z |
work_keys_str_mv | AT zhuxiaodong hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT huangcheng hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT shenyinghao hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT xubin hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT geningling hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT jiyuan hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT quxudong hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT chenlingli hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT chenyi hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT limeiling hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT zhujinjin hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT tangzhaoyou hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT zhoujian hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT fanjia hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma AT sunhuichuan hepatectomyafterconversiontherapyusingtyrosinekinaseinhibitorsplusantipd1antibodytherapyforpatientswithunresectablehepatocellularcarcinoma |